Latest news with #RickDoblin
Forbes
12-05-2025
- Health
- Forbes
Clinicians Invited To Explore Breakthroughs In Psychedelics At PS2025
Rick Doblin, Ph.D., founder and president of the Multidisciplinary Association for Psychedelic ... More Studies (MAPS) at PS2023. Psychedelic Science 2025 (PS2025) is inviting trauma therapists and other mental health professionals to attend its upcoming conference, which is designed for licensed clinicians. The event aims to inform attendees about psychedelic-assisted therapy modalities and other therapeutic tools, offering opportunities to engage with the latest research from leading experts in the field. Organizers believe these fundamental tools can arm health professionals with an expanded therapeutic toolkit to address mental health conditions. PS2025 will be hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS), taking place on June 16–20. It will return this year at the Colorado Convention Center in Denver. Keynote speakers—educating about recent breakthroughs in psychedelics—include New York Times bestseller Bessel van der Kolk, former U.S. senator Kyrsten Sinema, author Paul Stamets, Oprah Daily Editorial Director Pilar Guzmán, MAPS Founder Rick Doblin, neuroscientist Robin Carhart-Harris, and former congressman Tim Ryan. The event's Therapy Track programming was created specifically for licensed clinicians. It will feature select CE/CME-accredited workshops on psychedelic-assisted therapy modalities, ethics, and integration. There will also be data-driven sessions based on peer-reviewed research and clinical application, culturally responsive programming and diverse practitioner voices, and opportunities to connect with global experts in trauma-informed psychedelic care. Joseph McCowan, Psy.D., a member of the Lykos Board of Directors and chair of the PS2025 Therapy ... More Curatorial Committee Joseph McCowan, Psy.D., a member of the Lykos Board of Directors and chair of the PS2025 Therapy Curatorial Committee, emphasized the importance of meeting with clinicians, regardless of their experience with psychedelics. 'The Therapy Track at PS2025 is designed to meet clinicians where they are. Whether they're just beginning to explore psychedelic-assisted therapy or already immersed in the work, our goal is to equip mental health professionals with the tools, training, and connections they need to safely and effectively incorporate psychedelic-assisted therapy into their practice,' McCowan wrote in an exclusive statement. 'With CE-accredited workshops, real-world clinical case studies, and sessions that span ethics, integration, and emerging modalities, this year's conference is a unique opportunity for clinicians to engage with the science—and shape the future—of psychedelic care,' McCowan said. The event's Therapist Track includes the following handful of sessions: A full list of speakers and workshops were announced, providing evidence-based, trauma-informed practices. Workshops and sessions will be led by industry-leading researchers, therapists, and clinicians. Among many other topics, leading researchers hope to dispel myths about substances such as MDMA. PS2025 will also feature workshops, some of which will provide CE/CME credits: Former secretary of energy and former Texas governor Rick Perry speaks at PS2023. On May 8, PS2025's expanded Business Track was announced. 'Psychedelic Science 2025 is where science, business, and policy converge to shape the next leap forward,' Amy Emerson, founder & former CEO of Lykos Therapeutics, said in the announcement. 'The psychedelic industry is entering a critical phase of maturation—one that demands not just resilience, but collaboration, standardization, and strategic investment. To translate groundbreaking research into safe, effective, and accessible treatments, we must build an ecosystem that unites researchers, regulators, clinicians, and policymakers. Psychedelic medicine isn't just an investment opportunity—it's a collective movement to transform mental health care. Now is the time for bold, cross-disciplinary action to build a sustainable future where psychedelic therapies are not just innovative, but scalable, trusted, and transformative.' As psychedelic-assisted therapies become closer on the horizon, PS2025 aims to prepare mental health professionals for what's next. Additional speakers and conference sessions will continue to be announced in the weeks leading up to the conference.
Yahoo
21-04-2025
- Health
- Yahoo
Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball' Featuring Leading Psychedelic Experts
Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled "Gazing Through the Crystal Ball." The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates. Register here For more information: Featured Speakers Include: Rick Doblin, PhD – Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). A trailblazer in psychedelic-assisted therapy, Dr. Doblin has dedicated his career to establishing safe, legal, and ethical uses of psychedelics through rigorous scientific research. Robin Carhart-Harris, PhD – Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco (UCSF). Dr. Carhart-Harris is widely recognized for his pioneering work in psychedelic neuroscience and has led several landmark clinical studies on psilocybin and other compounds. Dr. Adi Zuloff-Shani – Chief Executive Officer of Clearmind Medicine. Dr. Zuloff-Shani brings decades of clinical and regulatory expertise and currently leads the development of Clearmind's innovative treatment for Alcohol Use Disorder (AUD), CMND-100, which recently advanced into FDA-approved clinical trials. Mark Haden – VP Business Development of Clearmind. Adjunct Professor at the University of British Columbia School of Population and Public Health and former Executive Director of MAPS Canada. Mr. Haden is a leading voice in drug policy reform and has worked extensively on public health-based approaches to psychedelic regulation and integration. The panel discussion will be moderated by Shannon Smadella, wellness advocate, executive consultant and podcast host. Ms. Smadella is a recognized voice in the psychedelic space and has played a key role in public engagement and awareness through events, such as World Psychedelics Day and MAPS Canada collaborations. Register here For additional information or media inquiries, please contact Clearmind at invest@ About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relations invest@ Telephone: (604) 260-1566 US: CMND@ General Inquiries Info@ Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
Associated Press
21-04-2025
- Health
- Associated Press
Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball' Featuring Leading Psychedelic Experts
Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce its upcoming live webinar titled 'Gazing Through the Crystal Ball.' The event is scheduled for May 21, 2025, at 12:00 PM ET (9:00 AM PT) and will feature a distinguished panel of experts discussing the evolving landscape of psychedelic science and business in the context of changing FDA policies and political climates. Register here For more information: Featured Speakers Include: Rick Doblin, PhD – Founder and President of the Multidisciplinary Association for Psychedelic Studies (MAPS). A trailblazer in psychedelic-assisted therapy, Dr. Doblin has dedicated his career to establishing safe, legal, and ethical uses of psychedelics through rigorous scientific research. Robin Carhart-Harris, PhD – Ralph Metzner Distinguished Professor of Neurology and Psychiatry at the University of California, San Francisco (UCSF). Dr. Carhart-Harris is widely recognized for his pioneering work in psychedelic neuroscience and has led several landmark clinical studies on psilocybin and other compounds. Dr. Adi Zuloff-Shani – Chief Executive Officer of Clearmind Medicine. Dr. Zuloff-Shani brings decades of clinical and regulatory expertise and currently leads the development of Clearmind's innovative treatment for Alcohol Use Disorder (AUD), CMND-100, which recently advanced into FDA-approved clinical trials. Mark Haden – VP Business Development of Clearmind. Adjunct Professor at the University of British Columbia School of Population and Public Health and former Executive Director of MAPS Canada. Mr. Haden is a leading voice in drug policy reform and has worked extensively on public health-based approaches to psychedelic regulation and integration. The panel discussion will be moderated by Shannon Smadella, wellness advocate, executive consultant and podcast host. Ms. Smadella is a recognized voice in the psychedelic space and has played a key role in public engagement and awareness through events, such as World Psychedelics Day and MAPS Canada collaborations. Register here For additional information or media inquiries, please contact Clearmind at [email protected]. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND' and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relations [email protected] Telephone: (604) 260-1566 US: [email protected] General Inquiries [email protected] Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
